The IRA is a ‘disguised form of patent reform’

By scrutinizing how the development paths of three transformational drugs on the market today would have differed if the Inflation Reduction Act had been in place at the time, a new study by the National Pharmaceutical Council shows how companies will have to navigate the new waters.

The IRA isn’t like a dam that completely blocks the flow of drug development. It is more like a set of boulders that have been placed in a stream, creating treacherous obstacles and rapids. Drug development will continue, but its path will be inexorably altered. ...